- New York NY, US Steven Burakoff - New York NY, US H. Umit Kaniskan - New York NY, US Sansana Sawasdikosol - New York NY, US He Chen - New York NY, US Joshua Brody - New York US, US Nina Bhardwaj - New York NY, US
International Classification:
A61K 47/55 A61K 39/395 A61K 47/54 A61P 35/00
Abstract:
Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation/disruption compounds including a HPK1 ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated diseases.
Compositions And Methods For Treating Alk-Mediated Cancer
- New york NY, US - Chapel Hill NC, US Jing Liu - New York NY, US Chengwei Zhang - New York NY, US Xiaoran Han - Chapel Hill NC, US He Chen - New York NY, US Pu Wang - Chapel Hill NC, US
Heterobifunctional small molecules including anaplastic lymphoma kinase (ALK) ligand conjugated to a degradation/disruption tag through a linker, which selectively degrade/disrupt ALK, ALK fusion proteins, and/or ALK mutant proteins, and compositions and methods of using such degraders/disruptors to treat ALK-mediated cancer are provided.